Europe's drug advisory body, the EMA's CHMP, has recommended marketing authorization for three oncology medicines at its September 2026 meeting. The trio targets two solid tumor types: ALK-positive non-small cell lung cancer (NSCLC) and epithelial ovarian/fallopian tube/peritoneal cancers. If the European Commission gives the final green light — typically within ~67 days — all three could be available across the EU by Q4 2026.

Here's the breakdown of each drug: Gevalka (ensartinib) is an oral ALK inhibitor for ALK-positive advanced NSCLC. In the phase 3 eXalt3 trial, it nearly doubled progression-free survival vs. crizotinib and dramatically improved intracranial response rates. Lifyorli (relacorilant), a glucocorticoid receptor antagonist, is used with nab-paclitaxel for platinum-resistant ovarian cancer, improving both PFS and overall survival without requiring biomarker selection. Sepalna (senaparib), a PARP inhibitor, is a maintenance therapy after first-line platinum-based chemo, cutting the risk of progression or death by 57% regardless of BRCA status.

By the Numbers:

• Ensartinib vs. crizotinib median PFS: 25.8 vs. 12.7 months (HR 0.51)
• Ensartinib intracranial response rate: 63.6% vs. 21.1% with crizotinib
• Relacorilant + nab-paclitaxel median OS: 16.0 months; PFS HR: 0.70
• Senaparib reduced progression/death risk by 57%; placebo median PFS: 13.6 months

Why it matters: These approvals would meaningfully expand the EU oncology toolkit — offering a stronger first-line ALK inhibitor, a chemo-sensitizing combo for hard-to-treat ovarian cancer, and a biomarker-agnostic maintenance PARP inhibitor — addressing significant unmet needs across both tumor types.